Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 70   

Articles published

BMY 55.95 -0.25 (-0.44%)
price chart
Bristol-Myers Squibb - Abilify
And finally... There is Bristol-Myers ($BMY) and its bad behavior. Its 2007 settlement covered a number of violations, such as gaming the system to jack up prices on Serzone.
Bristol-Myers Squibb (BMY) Acquires Amylin (AMLN) for $31/Share
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) agreed to be acquired by Bristol-Myers Squibb Company (NYSE: BMY) for $31.00 per share in cash, or approximately $5.3 billion.
Bristol-Myers in Deal for Amylin Valued at $7 Billion  New York Times (blog)
Bristol to Buy Amylin in $5.3 Billion Deal  Wall Street Journal
BBDO, CDM Said to Win Big Bristol-Myers Squibb Brand
Omnicom agencies BBDO New York and The CDM Group have been given U.S. creative lead responsibilities for Bristol-Myers Squibb's Abilify antidepressant drug, sources said. The brand, which had been at Digitas Health, spent $133.7 million in U.S. ...
Bristol-Myers Hits Sandoz Over Generic Hepatitis Drug
Law360, New York (June 21, 2012, 7:39 PM EDT) -- Bristol-Myers Squibb Co. on Thursday filed suit in Delaware federal court alleging Sandoz Inc.'s plan to make a generic version of the hepatitis B drug Baraclude would lead to infringement of BMS' patent ...
Dying man fights to get experimental drug from Bristol-Myers Squibb
Darcy Doherty, 48, is dying of cancer and believes his last chance at life is an experimental drug that a pharmaceutical company refuses to give him. Doherty, shown with wife Rebecca at their Toronto home, is battling to get the firm to change its mind.
Six-Year Follow-Up Data for SPRYCEL� (dasatinib) 100 mg Once Daily ...
Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL� (dasatinib) in Philadelphia ...
ASCO: Paclitaxel Bests New Drugs in Breast Cancer
CHICAGO -- Patients with metastatic breast cancer did just as well -- and maybe better -- with paclitaxel-based chemotherapy compared with two newer, more expensive agents, results of a randomized trial showed.
New CEO at high-flying Mead Johnson catches a company at its peak
The Denmark native and 14-year company veteran is taking over a Glenview-based business whose net sales have climbed 30 percent, to $3.7 billion, since 2009, when it was spun off from Bristol-Myers Squibb Co. Mr. Jakobsen, 50, was named chief ...
Insight: Top heart doctors fret over new blood thinners
Boehringer Ingelheim said it is working on an antidote, but declined to elaborate. Johnson & Johnson said it is not developing an antidote, but is monitoring early efforts by other drugmakers to come up with one.
Docs fret over new blood thinners  Free Malaysia Today
ADA: Fish Oil Takes Down Lipids in Diabetics
PHILADELPHIA -- Diabetics with mixed dyslipidemia who were on statins improved their lipid profiles, without worsening glycemic control, with a novel omega-3 fatty acid drug, according to researchers here.